Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 78
Selected: 0
NCT IDTitle
NCT05277454Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
NCT03091192Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT04322539A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
NCT04557397Fruquintinib CYP3A Inhibitor and Inducer Study
NCT05015621A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
NCT02590952A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
NCT04645940Fruquintinib Food Effect and Proton Pump Inhibitor Study
NCT03684967Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC
NCT04169672Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
NCT03128164A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
NCT02590965A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
NCT04755088Surufatinib Renal Impairment Study
NCT02631642A Study of HMPL-689 in Healthy Volunteers
NCT04372407A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects
NCT05522738Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
NCT03160833A Study of HMPL-453 in Patients With Advanced Solid Malignancies
NCT03860532Phase I Clinical Trial in Healthy Male Volunteers
NCT02601248Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor
NCT02105129A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
NCT02374645A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC
NCT02196688Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT02314819A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)
NCT03231501HMPL-813 in Treating Patients With Glioblastoma
NCT02252913A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer
NCT02133157Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
NCT04290325HMPL-453 in Advanced Malignant Mesothelioma
NCT03977090Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer
NCT05015608Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
NCT04849351Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
NCT05173142A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
NCT02503033A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT03223376A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
NCT02857998A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
NCT03483948Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
NCT03860948A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers
NCT02976116A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
NCT04510649Surufatinib DDI With a PPI and a CYP3A Inducer
NCT04372394A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects
NCT04716634Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
NCT04755075Surufatinib Hepatic Impairment Study
NCT03627520A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]Sulfatinib
NCT04923932Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
NCT05511051A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
NCT02966171A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies
NCT02897479A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer
NCT02966821Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma
NCT01805791A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
NCT01955304Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects
NCT00659802Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
NCT02614495Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma